

Ke-da Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3776027/publications.pdf>

Version: 2024-02-01

121
papers

5,380
citations

117625

34
h-index

91884

69
g-index

121
all docs

121
docs citations

121
times ranked

7860
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast Cancer Vaccines: Disappointing or Promising?. <i>Frontiers in Immunology</i> , 2022, 13, 828386.	4.8	30
2	Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis. <i>Nature Communications</i> , 2022, 13, 791.	12.8	16
3	De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort. <i>Cancer</i> , 2022, 128, 1748-1756.	4.1	18
4	Alloimperatorin activates apoptosis, ferroptosis, and oxeiptosis to inhibit the growth and invasion of breast cancer cells in vitro. <i>Biochemistry and Cell Biology</i> , 2022, 100, 213-222.	2.0	15
5	Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2807-2817.	7.0	30
6	Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 884-892.	6.3	21
7	Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 371-380.	2.5	1
8	The advance of adjuvant treatment for triple-negative breast cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	3.0	11
9	Association Between a Tri-allelic Polymorphism in the Estrogen Metabolism Oxidoreductase NRH:Quinone Oxidoreductase 2 Gene and Risk of Breast Cancer by Molecular Subtype. <i>Frontiers in Genetics</i> , 2021, 12, 658285.	2.3	3
10	Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Early Triple-Negative Breast Cancer—Reply. <i>JAMA Oncology</i> , 2021, 7, 461.	7.1	1
11	Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1352-1359.	6.3	7
12	Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 11, 100158.	2.9	9
13	Estrogen receptor-low breast cancer: Biology chaos and treatment paradox. <i>Cancer Communications</i> , 2021, 41, 968-980.	9.2	23
14	Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery. <i>Frontiers in Oncology</i> , 2021, 11, 690658.	2.8	4
15	Prognostic Effect of Microenvironment Phenotype in Triple-Negative Breast Cancer: Biomarker Analysis of a Prospective Trial. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 752154.	3.5	2
16	Delayed initiation of radiation therapy is associated with inferior outcomes for breast cancer patients with hormone receptor-negative tumors after breast-conserving surgery. <i>Gland Surgery</i> , 2021, 10, 2631-2643.	1.1	4
17	Homologous recombination deficiency and glycolysis-related pathway in adjuvant chemotherapy for triple-negative breast cancer: A genomic landscape and biomarker assessment of the PATTERN trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e513.	4.0	0
18	Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. <i>Nature Communications</i> , 2020, 11, 5679.	12.8	41

#	ARTICLE	IF	CITATIONS
19	Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer. <i>Npj Precision Oncology</i> , 2020, 4, 23.	5.4	1
20	Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1390.	7.1	115
21	Interaction of two functional genetic variants LOXL1 rs1048661 and VEGFA rs3025039 on the risk of age-related macular degeneration in Chinese women. <i>Annals of Translational Medicine</i> , 2020, 8, 818-818.	1.7	1
22	Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 570981.	2.8	7
23	Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 342-342.	1.7	2
24	Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes. <i>Scientific Reports</i> , 2020, 10, 7648.	3.3	41
25	HER2 overexpression in ductal carcinoma in situ is associated with ipsilateral breast cancer recurrence after conservative surgery. <i>Translational Cancer Research</i> , 2020, 9, 3787-3793.	1.0	2
26	Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1774-1784.	1.6	64
27	Abstract P3-14-04: Tailored duration of adjuvant trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer. , 2020, , .		0
28	Abstract P4-09-01: Clinical sequencing characterizes the genomic landscape and actionable mutations of Chinese breast cancer. , 2020, , .		0
29	Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis. <i>Scientific Reports</i> , 2019, 9, 286.	3.3	29
30	Complicated prognostic values of CCL28 in breast cancer by subtype. <i>Journal of Thoracic Disease</i> , 2019, 11, 777-787.	1.4	9
31	Comparison of Time-Dependent Contralateral Breast Cancer Incidence Requires Comparable Lengths of Follow-Up. <i>Journal of Clinical Oncology</i> , 2019, 37, 1515-1516.	1.6	1
32	Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-“positive, human epidermal growth factor receptor 2”negative breast cancer (CBCSG036): A randomized, controlled, multicenter trial. <i>Cancer</i> , 2019, 125, 2185-2193.	4.1	17
33	Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5002-5014.	7.0	269
34	Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity. <i>Clinical Cancer Research</i> , 2019, 25, 3658-3672.	7.0	31
35	Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. <i>Cancer Cell</i> , 2019, 35, 428-440.e5.	16.8	571
36	The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. <i>Science Advances</i> , 2019, 5, eaat9820.	10.3	95

#	ARTICLE	IF	CITATIONS
37	Toll-like receptor 3 acts as a suppressor gene in breast cancer initiation and progression: a two-stage association study and functional investigation. <i>Oncolmmunology</i> , 2019, 8, e1593801.	4.6	15
38	Toll-like receptor 3 -926T>A increased the risk of breast cancer through decreased transcriptional activity. <i>Oncolmmunology</i> , 2019, 8, e1673126.	4.6	8
39	A Large-Scale, Exome-Wide Association Study of Han Chinese Women Identifies Three Novel Loci Predisposing to Breast Cancer. <i>Cancer Research</i> , 2018, 78, 3087-3097.	0.9	19
40	The effect of delayed adjuvant chemotherapy on relapse of triple-negative breast cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 2837-2841.	1.4	9
41	Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer. <i>Theranostics</i> , 2018, 8, 6386-6399.	10.0	26
42	Effect of functional genetic variants in chemokine decoy receptors on the recurrence risk of breast cancer. <i>Cancer Medicine</i> , 2018, 7, 5497-5504.	2.8	6
43	Interaction between glutathione S-transferase M1 null/present polymorphism and adjuvant chemotherapy influences the survival of breast cancer. <i>Cancer Medicine</i> , 2018, 7, 4202-4207.	2.8	20
44	The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. <i>International Journal of Cancer</i> , 2017, 141, 129-142.	5.1	89
45	Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent. <i>Oncotarget</i> , 2017, 8, 46549-46556.	1.8	36
46	Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 33.	5.0	176
47	Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4859-4869.	7.0	60
48	A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer. <i>BMC Cancer</i> , 2016, 16, 606.	2.6	11
49	Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1653-1662.	7.0	68
50	Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. <i>Cancer Research</i> , 2016, 76, 2105-2114.	0.9	168
51	New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 24824-24831.	1.8	16
52	Intratumoral expression of CCR3 in breast cancer is associated with improved relapse-free survival in luminal-like disease. <i>Oncotarget</i> , 2016, 7, 28570-28578.	1.8	13
53	Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer. <i>BMC Medicine</i> , 2015, 13, 254.	5.5	21
54	Effect of radiotherapy on survival of women with locally excised ductal carcinoma in situ of the breast: a Surveillance, Epidemiology, and End Results population-based analysis. <i>OncoTargets and Therapy</i> , 2015, 8, 1407.	2.0	3

#	ARTICLE	IF	CITATIONS
55	Polymorphisms in the kinesin-like factor 1 B gene and risk of epithelial ovarian cancer in Eastern Chinese women. <i>Tumor Biology</i> , 2015, 36, 6919-6927.	1.8	5
56	CASP7 variants modify susceptibility to cervical cancer in Chinese women. <i>Scientific Reports</i> , 2015, 5, 9225.	3.3	13
57	Different Patterns in the Prognostic Value of Age for Breast Cancer-Specific Mortality Depending on Hormone Receptor Status: A SEER Population-Based Analysis. <i>Annals of Surgical Oncology</i> , 2015, 22, 1102-1110.	1.5	27
58	Abstract P1-04-04: Activating HER2 mutations promote oncogenesis and resistance to HER2-targeted therapies in breast cancer. , 2015, , .		1
59	Abstract P1-12-02: Effect of using LHRH analog during chemotherapy (CT) on premature ovarian failure and prognosis in premenopausal patients with early-stage, hormone receptor-positive breast cancer: The primary analysis of a randomized controlled phase III trial. , 2015, , .		3
60	Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women. <i>PLoS ONE</i> , 2015, 10, e0129741.	2.5	40
61	A Prospective Evaluation of the Association between a Single Nucleotide Polymorphism rs3775291 in Toll-Like Receptor 3 and Breast Cancer Relapse. <i>PLoS ONE</i> , 2015, 10, e0133184.	2.5	13
62	Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. <i>Oncotarget</i> , 2015, 6, 9600-9611.	1.8	45
63	Difference between observed and expected number of involved lymph nodes reflects the metastatic potential of breast cancer independent to intrinsic subtype. <i>Oncotarget</i> , 2015, 6, 16686-16697.	1.8	7
64	Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse. <i>Oncotarget</i> , 2015, 6, 26519-26527.	1.8	18
65	Abstract P1-04-02: Exome sequencing identified emergence of HER2 kinase domain mutations in trastuzumab-resistant breast cancer. , 2015, , .		0
66	Abstract P6-08-28: Prognostic and predictive value of an integrated mRNA-lncRNA signature in triple-negative breast cancer: A comprehensive transcriptome analysis. , 2015, , .		0
67	The Effect of Laterality and Primary Tumor Site on Cancer-Specific Mortality in Breast Cancer: A SEER Population-Based Study. <i>PLoS ONE</i> , 2014, 9, e94815.	2.5	35
68	ER-Poor and HER2-Positive: A Potential Subtype of Breast Cancer to Avoid Axillary Dissection in Node Positive Patients after Neoadjuvant Chemo-Trastuzumab Therapy. <i>PLoS ONE</i> , 2014, 9, e114646.	2.5	11
69	PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2014, 7, 543.	2.0	14
70	Reply to comparative analysis of <i>GATA3</i> mutation profiles between Asian and Western patients with breast cancer: Is there really a difference?. <i>Cancer</i> , 2014, 120, 2779-2780.	4.1	0
71	<i>GATA3</i> mutations define a unique subtype of luminal-like breast cancer with improved survival. <i>Cancer</i> , 2014, 120, 1329-1337.	4.1	60
72	Favorable Prognostic Impact in Loss of <i>TP53</i> and <i>PIK3CA</i> Mutations after Neoadjuvant Chemotherapy in Breast Cancer. <i>Cancer Research</i> , 2014, 74, 3399-3407.	0.9	37

#	ARTICLE	IF	CITATIONS
73	Enriched variations in TEK4 and breast cancer resistance to paclitaxel. <i>Nature Communications</i> , 2014, 5, 3802.	12.8	34
74	Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8838-8843.	7.1	99
75	Survival Benefit From Response-Guided Approach: A Direct Effect of More Effective Cytotoxic Regimens or an Indirect Effect of Chemotherapy-Induced Amenorrhea?. <i>Journal of Clinical Oncology</i> , 2014, 32, 1282-1283.	1.6	3
76	Absence of multiple atypical chemokine binders (ACBs) and the presence of VEGF and MMP-9 predict axillary lymph node metastasis in early breast carcinomas. <i>Medical Oncology</i> , 2014, 31, 145.	2.5	15
77	Breast cancer in China. <i>Lancet Oncology</i> , The, 2014, 15, e279-e289.	10.7	1,168
78	Preoperative Measurement of Breast Cancer Overestimates Tumor Size Compared to Pathological Measurement. <i>PLoS ONE</i> , 2014, 9, e86676.	2.5	10
79	A recessive variant of <i>XRCC4</i> predisposes to non- <i>BRCA1/2</i> breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization. <i>Oncotarget</i> , 2014, 5, 12218-12232.	1.8	5
80	Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women. <i>Human Genetics</i> , 2013, 132, 301-312.	3.8	40
81	Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 2723-2733.	7.0	146
82	Weekly Paclitaxel/Carboplatin/Trastuzumab Therapy Improves Pathologic Complete Remission in Aggressive HER2-Positive Breast Cancers, Especially in Luminal-B Subtype, Compared With a Once-Every-3-Weeks Schedule. <i>Oncologist</i> , 2013, 18, 511-517.	3.7	20
83	The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2013, 19, 6853-6862.	7.0	68
84	Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2013, 13, 240.	2.6	87
85	Effect of Genetic Variants in Two Chemokine Decoy Receptor Genes, DARC and CCBP2, on Metastatic Potential of Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e78901.	2.5	23
86	Immediate Postmastectomy Breast Reconstruction Showed Limited Advantage in Patient Survival after Stratifying by Family Income. <i>PLoS ONE</i> , 2013, 8, e82807.	2.5	11
87	Hazard of Breast Cancer-Specific Mortality among Women with Estrogen Receptor-Positive Breast Cancer after Five Years from Diagnosis: Implication for Extended Endocrine Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2201-E2209.	3.6	65
88	Association of <i>HER-2</i> Copy Number and <i>HER-2/CEP-17</i> Ratio with Neoadjuvant Taxane-Containing Chemotherapy Sensitivity in Locally Advanced Breast Cancer. <i>Oncologist</i> , 2012, 17, 792-800.	3.7	8
89	Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptor-positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 3002-3011.	1.5	44
90	Effect of Large Tumor Size on Cancer-Specific Mortality in Node-Negative Breast Cancer. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1171-1180.	3.0	37

#	ARTICLE	IF	CITATIONS
91	Genetic Variants in Oxidative Stress-Related Genes Predict Chemoresistance in Primary Breast Cancer: A Prospective Observational Study and Validation. <i>Cancer Research</i> , 2012, 72, 408-419.	0.9	24
92	A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer. <i>Journal of Surgical Oncology</i> , 2012, 105, 577-585.	1.7	17
93	A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 307-313.	2.5	45
94	The associations between two polymorphisms in the interleukin-10 gene promoter and breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 27-31.	2.5	15
95	The two faces of autophagy and the pathological underestimation of DCIS. <i>Nature Reviews Cancer</i> , 2011, 11, 618-618.	28.4	3
96	ESR1 gene amplification: another mechanism regulating the cellular levels of ER α . <i>Nature Reviews Cancer</i> , 2011, 11, 823-823.	28.4	8
97	Different Distribution of Breast Cancer Subtypes in Breast Ductal Carcinoma in situ (DCIS), DCIS with Microinvasion, and DCIS with Invasion Component. <i>Annals of Surgical Oncology</i> , 2011, 18, 1342-1348.	1.5	64
98	Predicting Breast Cancer Recurrence Following Breast-Conserving Therapy: A Single-Institution Analysis Consisting of 764 Chinese Breast Cancer Cases. <i>Annals of Surgical Oncology</i> , 2011, 18, 2492-2499.	1.5	28
99	Coexpression of atypical chemokine binders (ACBs) in breast cancer predicts better outcomes. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 715-727.	2.5	40
100	A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 37-45.	2.5	43
101	RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 365-371.	2.5	22
102	Different Annual Recurrence Pattern Between Lumpectomy and Mastectomy: Implication for Breast Cancer Surveillance After Breast-Conserving Surgery. <i>Oncologist</i> , 2011, 16, 1101-1110.	3.7	20
103	Toll-like receptor 3 C1234T may protect against geographic atrophy through decreased dsRNA binding capacity. <i>FASEB Journal</i> , 2011, 25, 3489-3495.	0.5	54
104	Genetic contribution of GADD45A to susceptibility to sporadic and non-BRCA1/2 familial breast cancers: a systematic evaluation in Chinese populations. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 157-167.	2.5	9
105	Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 485-496.	2.5	27
106	Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 251-257.	2.5	43
107	Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 483-488.	2.5	35
108	No association between a progesterone receptor gene promoter polymorphism (+331G>A) and breast cancer risk in Caucasian women: evidence from a literature-based meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 853-858.	2.5	14

#	ARTICLE	IF	CITATIONS
109	XRCC2 Arg188His polymorphism is not directly associated with breast cancer risk: evidence from 37,369 subjects. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 219-225.	2.5	25
110	A Straightforward but Not Piecewise Relationship between Age and Lymph Node Status in Chinese Breast Cancer Patients. <i>PLoS ONE</i> , 2010, 5, e11035.	2.5	14
111	Tailoring Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A CYP2D6 Multiple-Genotype-Based Modeling Analysis and Validation. <i>PLoS ONE</i> , 2010, 5, e15649.	2.5	4
112	Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. <i>Human Molecular Genetics</i> , 2009, 18, 2502-2517.	2.9	31
113	Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 409-416.	2.5	147
114	Caution regarding genotyping methodology for a tri-allelic polymorphism in the novel breast cancer susceptibility gene NQO2. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 647-649.	2.5	5
115	A functional polymorphism in the promoter region of <i>GSTM1</i> implies a complex role for <i>GSTM1</i> in breast cancer. <i>FASEB Journal</i> , 2009, 23, 2274-2287.	0.5	46
116	Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1347-1354.	2.5	42
117	Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. <i>Breast</i> , 2007, 16, 307-315.	2.2	25
118	Development and Trends of Surgical Modalities for Breast Cancer in China: A Review of 16-Year Data. <i>Annals of Surgical Oncology</i> , 2007, 14, 2502-2509.	1.5	62
119	Immediate breast reconstruction with latissimus dorsi musculocutaneous flap: A suitable option for chinese women after mastectomy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2006, 18, 88-93.	2.2	1
120	De-Escalation of Five-Year Adjuvant Endocrine Therapy in Patients with Er-Low Positive Breast Cancer: Propensity-Matched Analysis from a Prospectively Maintained Cohort. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
121	Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection and Survival in Young Women with Breast Cancer: A Randomized Phase 3 Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0